TITLE

Hepatotoxicity Due to Troglitazone: Report of Two Cases and Review of Adverse Events Reported to the United States Food and Drug Administration

AUTHOR(S)
Kohlroser, James; Mathai, Jijy; Reichheld, James; Banner, Barbara F.; Bonkovsky, Herbert L.
PUB. DATE
January 2000
SOURCE
American Journal of Gastroenterology;Jan2000, Vol. 95 Issue 1, p272
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Two patients (a 48-year-old woman and a 62-year-old man) developed clinical and laboratory signs of hepatotoxicity due to troglitazone (Rezulin), a thiazolidinedione used in treatment of diabetes mellitus. There was no clear clinical evidence of drug allergy, although the woman experienced colitis before the onset of recognized hepatotoxicity. Liver biopsies showed bridging necrosis and fibrosis in the woman and hepatitis with granuioma formation in the man. The abnormalities in liver chemistries resolved promptly upon cessation of the drug. Cases involving 46 patients reported to the United States Food and Drug Administration are also reviewed. Troglitazone is a useful new oral antihyperglycemic agent, but in about 1.9% of patients hepatotoxicity has occurred, which may be severe and even fatal. Frequent monitoring of serum liver chemistries in patients taking the drug is essential.
ACCESSION #
17634511

 

Related Articles

  • Hepatotoxicity with thiazolidinediones: is it a class effect? Scheen, A.J. // Drug Safety;Sep2001, Vol. 24 Issue 12, p873 

    Decreased insulin sensitivity plays a major role in various human diseases, particularly type 2 diabetes mellitus, and is associated with a higher risk of atherosclerosis and cardiovascular complications. Thiazolidinediones, more commonly termed glitazones, are the first drugs to specifically...

  • Diabetes drug delays stir controversy. Wechsler, Jill // Managed Healthcare Executive;Apr2009, Vol. 19 Issue 4, p6 

    The article reports on the issue regarding the latest diabetes treatment safety information required by the Food and Drug Administration (FDA) in the U.S. It mentions that FDA has been alarmed to the new diabetes treatments due to its adverse effects to the cardiovascular system and cites the...

  • Ischaemic Colitis in Rheumatoid Arthritis Patients Receiving Tumour Necrosis Factor-α Inhibitors: An Analysis of Reports to the US FDA Adverse Event Reporting System. Salk, Allison; Stobaugh, Derrick; Deepak, Parakkal; Ehrenpreis, Eli // Drug Safety;2013, Vol. 36 Issue 5, p329 

    Background: Tumour necrosis factor-α (TNF-α) inhibitors are immunosuppressants, approved for the treatment and maintenance of rheumatoid arthritis (RA). Immunosuppression has been shown to induce ischaemic colitis (IC) in an animal model; however, a relationship between TNF inhibitors and...

  • New formulations.  // Pharmacy Today;Jan2009, Vol. 15 Issue 1, p16 

    The article reports on the approval given by the U.S. Food and Drug Administration to two therapeutic medications. Mesalamine extended-release 0.375 gram (g) capsules was approved for the maintenance of remission of ulcerative colitis in adults 18 years of age and older. Meanwhile, Acanya gel...

  • More frequent liver monitoring urged for Rezulin.  // Drug Topics;12/8/97, Vol. 141 Issue 23, p8 

    Reports on warnings issued by the United States Food and Drug Administration on side effects associated with the drug Rezulin on the liver. Reasons for warnings; Recommendations made by the organization.

  • Weighing Risks and Benefits of Liraglutide � The FDA's Review of a New Antidiabetic Therapy. Parks, Mary; Rosebraugh, Curtis // New England Journal of Medicine;3/4/2010, Vol. 362 Issue 9, p774 

    The article comments on the benefits and risks of liraglutide, a glucagon-like-peptide-1 (GLP-1) receptor agonist that can enhance glycemic control of patients with type 2 diabetes. According to the authors, the U.S. Food and Drug Administration (FDA) has approved liraglutide because it may...

  • FDA announces ongoing safety review of olmesartan.  // Endocrine Today;Jul2010, Vol. 8 Issue 7, p13 

    The article reports on a review being conducted by the U.S. Food and Drug Administration (FDA) on the possible association between olmesartan and a higher rate for death from a cardiovascular cause in patients with type 2 diabetes.

  • FDA Actions. Elliott, William E. // Alternative Medicine Alert;Nov2010 Supplement, p2 

    The article discusses several actions taken by the U.S. Food and Drug Administration (FDA), as of November 2010. The FDA is restricting the use of rosiglitazone for type 2 diabetic patients who cannot control their diabetes. The FDA has approved Fingolimod, an oral drug used to reduce relapses...

  • Incretin mimetics potential link with pancreatic pre-cancer.  // Reactions Weekly;3/16/2013, Issue 1444, p5 

    The article reports that the U.S. Food and Drug Administration (FDA) is examining the links between the use of incetin mimetics and the risks of pancreatitis and pancreatic duct metaplasia in type 2 diabetes patient.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics